XOMA Corporation (XOMA) : Analyst Rating Update

XOMA Corporation (XOMA) : The consensus on XOMA Corporation (XOMA) based on 6 analyst recommendation on the company stock is 2.67, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 1 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

XOMA Corporation (XOMA) : The most positive equity analysts on XOMA Corporation (XOMA) expects the shares to touch $3, whereas, the least positive believes that the stock will trade at $1 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $1.62 with an expected fluctuation of $1.2 from the mean.

XOMA Corporation (NASDAQ:XOMA): The stock opened at $0.56 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.58 for the day. The stock traded down to $0.54 during the day, due to lack of any buying support eventually closed down at $0.54 with a loss of -2.70% for the day. The stock had closed at $0.56 on the previous day. The total traded volume was 393,504 shares.

The company shares have dropped -84.95% from its 1 Year high price. On Jul 13, 2015, the shares registered one year high at $4.93 and the one year low was seen on Jun 29, 2016. The 50-Day Moving Average price is $0.63 and the 200 Day Moving Average price is recorded at $0.84.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *